Silexion Therapeutics (NASDAQ:SLXN) Posts Quarterly Earnings Results, Beats Expectations By $12.05 EPS

Silexion Therapeutics (NASDAQ:SLXN) posted its quarterly earnings results on Friday, May 15th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($12.90) by $12.05, Zacks reports.

Silexion Therapeutics Trading Up 2.7%

NASDAQ:SLXN opened at $0.43 on Friday. The stock has a market capitalization of $1.79 million, a PE ratio of -0.05 and a beta of -0.29. The firm has a fifty day simple moving average of $8.59 and a 200 day simple moving average of $17.01. Silexion Therapeutics has a 1-year low of $0.23 and a 1-year high of $22.36.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Wednesday, March 18th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.